This public procurement record has 4 releases in its history.

Award

24 Apr 2026 at 09:59

Award

25 Feb 2026 at 13:10

Tender

18 Dec 2025 at 15:49

Planning

24 Oct 2025 at 12:45

Summary of the contracting process

The NHS England has concluded its procurement process for the National Framework concerning Transition Products, specifically Nintedanib and Dalbavancin. This procurement process took an open procedure approach and culminated in awarding contracts to multiple suppliers. The award announcement was made on 24th April 2026, following the commencement of the framework on 1st May 2026, set to run until 30th September 2027, with potential extensions up to 24 months upon the authority's discretion. This framework covers pharmaceutical goods across various regions in the United Kingdom, with each lot subject to specific delivery timelines and requirements. The process operated under the legal basis provided by the UK Public General Acts 2023/54 and was coordinated by NHS Medicine Value & Access from Wellington House, London.

This NHS procurement framework offers substantial business growth opportunities for pharmaceutical suppliers looking to extend their market reach across the UK healthcare sector. The open competition encourages diverse participation, allowing large enterprises and SMEs to bid, thus supporting innovation and capability expansion in developing transition pharmaceutical products. Suitable businesses particularly include those with expertise in pharmaceutical products, looking to supply NHS-affiliated organisations, and capable of sustaining a reliable supply chain. This initiative not only strengthens supplier relationships but also fosters an environment where competitive pricing and quality assurance can play pivotal roles in winning contracts within the NHS procurement landscape. Such frameworks will help companies establish long-term operations within the region, reaching more purchasing points covered by the NHS Medicines Value & Access.

How relevant is this notice?

Notice Title

NHS National Framework for Transition Products (Nintedanib and Dalbavancin)

Notice Description

Project title: NHS National Framework for Transition Products (Nintedanib and Dalbavancin) commencing 1st May 2026 Offer reference number: CM/TNS/25/5736 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to a maximum of 24 months. CM/TNS/25/5736 Nintedanib and Dalbavancin Lot 1 DLN/DNW: 01/05/2026 to 30/09/2027 (17 months) Lot 2 DLS/DNE: 01/05/2026 to 31/05/2027 (13 months) Lot 3 DCE/DSW: 01/05/2026 to 31/01/2027 (9 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

Lot Information

Lot 1

Renewal: Option or options to extend (at the discretion of the Authority) up to a maximum of 24 months

Planning Information

NHS England is seeking to engage with suppliers that are planning to launch any of the molecules that will be covered by this procurement. Interested suppliers will be invited to a virtual preliminary market engagement meeting. The purpose of these sessions is to update suppliers regarding timelines and to discuss product details, product launches during the proposed framework period, tender structure, and KPI's. Please contact katie.noonan@nhs.net or marie.graney1@nhs.net to register your interest in tendering for this framework. Please indicate which products your company is planning to bring to market in your response.

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-05d361
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/037405-2026
Current Stage
Award
All Stages
Planning, Tender, Award

Procurement Classification

Notice Type
UK7 - Contract Details Notice
Procurement Type
Framework
Procurement Category
Goods
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
SME
Awardee Scale
Large, SME

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products


CPV Codes

33600000 - Pharmaceutical products

Notice Value(s)

Tender Value
£115,756,000 £100M-£1B
Lots Value
£115,756,000 £100M-£1B
Awards Value
£14,758,000 £10M-£100M
Contracts Value
£14,758,000 £10M-£100M

Notice Dates

Publication Date
24 Apr 20264 months ago
Submission Deadline
28 Jan 2026Expired
Future Notice Date
17 Dec 2025Expired
Award Date
25 Feb 20266 months ago
Contract Period
1 May 2026 - 30 Sep 2027 1-2 years
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Complete
Awards Status
Active, Pending
Contracts Status
Active

Contracting Authority (Buyer)

Main Buyer
NHS England
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
LONDON
Postcode
SE1 8UG
Postcode Area
South East London
Country
England

Major Region (ITL 1)
TLI London
Basic Region (ITL 2)
TLI4 Inner London - East
Small Region (ITL 3)
TLI45 Lambeth
Delivery Location
TLC North East (England), TLD North West (England), TLF East Midlands (England), TLG West Midlands (England), TLH East (England), TLJ South East (England), TLK South West (England)

Local Authority
Lambeth
Electoral Ward
Waterloo & South Bank
Westminster Constituency
Vauxhall and Camberwell Green

Supplier Information

Number of Suppliers
9
Supplier Names

ACCORD-UK LTD

Baxter Healthcare Ltd

CELIX PHARMA LTD

DR REDDY'S LABORATORIES (UK) LIMITED

Glenmark Pharmaceuticals Europe Limited

MILPHARM LIMITED

REIG JOFRE UK LIMITED

WOCKHARDT UK LIMITED

ZENTIVA PHARMA UK LIMITED

Further Information

Notice Documents

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...